Certara Completes Acquisition of Pinnacle 21 PRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire...

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts PRINCETON, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical...

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal...

Trivedi Global, Inc. and Dr. William Plikerd Announce Results on the Impact of a Biofield Treated Proprietary Formulation to Combat Autoimmune and Inflammatory Disorders Columbus, OH, USA, May 22, 2018 (GLOBE NEWSWIRE) -- Dr. William Plikerd, an evidence-based healer today announces research results on the significant impact of a proprietary biofield energy healing...

Trivedi Global, Inc. in Association with Victoria Vannes Announces Research Results on an Energy Infused Proprietary Product to Combat Inflammation and Autoimmune Disorders Philadelphia, Pennsylvania. U.S.A., May 22, 2018 (GLOBE NEWSWIRE) -- Victoria Vannes, an evidence-based healer today announces research results on the significant impact of a proprietary biofield...